The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: Development of a novel therapeutic vaccine candidate

被引:10
|
作者
Liu, Yuanjie
Simsek, Ender
Norton, Pamela
Sinnathamby, Gomathinayagam
Philip, Ramila
Block, Timothy
Zhou, Tianlun
Mehta, Anand [1 ]
机构
[1] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Doylestown, PA 18902 USA
[2] Inst Hepatitis & Virus Res, Doylestown, PA 18902 USA
关键词
hepatitis B virus; glycosylation; secretion; antigen presentation; vaccine;
D O I
10.1016/j.virol.2007.03.042
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The signal sequences that mediate entry of the hepatitis B virus (HBV) envelope proteins into the endoplasmic reticulum (ER) are located within the S domain at positions 11-32 and at positions 80-98 (from the start of the S domain). In addition, hydrophobic patches at positions 160-184 and 189-210 of the S domain may also be involved in entry into the ER. The role of each of these domains in the entry of the HBV M glycoprotein into the ER was studied by deletion mutations of each of the signal sequences. Glycosylation of proteins was used as a marker of entry into the ER. Our results indicate that association with the ER could not be prevented by the deletion of either individual or combinations of the HBV signal sequences. M protein lacking signal sequence I was able to enter the ER and had limited secretion. In contrast, M protein lacking signal sequence 11 could not be secreted but still entered the ER. M protein lacking signal sequences I and 11, while still associated with the ER, was rapidly degraded by the cytosolic proteasome. The potential use of such a vector as a CTL vaccine was tested through an in vitro antigen presentation assay. In this assay, a DNA vaccine candidate lacking signal sequences I and 11 lead to a > 6-fold increase in CTL activation, as compared to the vector expressing wild type M protein. These results suggest that increased degradation of the HBV envelope proteins can lead to enhanced antigen presentation. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:10 / 19
页数:10
相关论文
共 11 条
  • [1] A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice
    Boudewijns, Robbert
    Ma, Ji
    Neyts, Johan
    Dallmeier, Kai
    JHEP REPORTS, 2021, 3 (04)
  • [2] A novel therapeutic HBV vaccine induces potent surface- and core-specific immunogenicity in mice, rhesus macaques and HBV transgenic mice
    Marshall, Jason D.
    Gresner, Marianne L.
    Heeke, Darren S.
    Buchmann, Pascale
    Martins, Eduardo
    Livingston, Brian D.
    Melber, Karl
    Van Nest, Gary
    HEPATOLOGY, 2007, 46 (04) : 302A - 302A
  • [3] P-GLYCOPROTEIN AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN ALLOTRANSPLANTATION. ROLE ON DENDRITIC CELL MATURATION AND LYMPHOCYTE PROLIFERATION
    Lloberas, Nuria
    Rama, Ines
    Cassis, Linda
    Llaudo, Ines
    Franquesa, Marcel-la
    Torras, Joan
    Cruzado, Josep M.
    Bestard, Oriol
    Benitez, Daniel
    Grinyo, Josep M.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 252 - 253
  • [4] A novel therapeutic HBV vaccine induces potent surface- and core-specific immunogenicity in mice rhesus macaques
    Gesner, Marianne L.
    Heeke, Darren S.
    Martins, Eduardo
    Livingston, Brian S.
    Van Nest, Gary
    Marshall, Jason D.
    FASEB JOURNAL, 2008, 22
  • [5] THE N-TERMINAL (PRE-S2) DOMAIN OF A HEPATITIS B-VIRUS SURFACE GLYCOPROTEIN IS TRANSLOCATED ACROSS MEMBRANES BY DOWNSTREAM SIGNAL SEQUENCES
    EBLE, BE
    LINGAPPA, VR
    GANEM, D
    JOURNAL OF VIROLOGY, 1990, 64 (03) : 1414 - 1419
  • [6] The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV
    Chinnakannan, Senthil K.
    Cargill, Tamsin N.
    Donnison, Timothy A.
    Ansari, M. Azim
    Sebastian, Sarah
    Lee, Lian Ni
    Hutchings, Claire
    Klenerman, Paul
    Maini, Mala K.
    Evans, Tom
    Barnes, Eleanor
    VACCINES, 2020, 8 (02)
  • [7] Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence-based affinity maturation
    Kielczewska, Agnieszka
    D'Angelo, Igor
    Amador, Maria Sheena
    Wang, Tina
    Sudom, Athena
    Min, Xiaoshan
    Rathanaswami, Palaniswami
    Pigott, Craig
    Foltz, Ian N.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (02)
  • [8] Altering DI of beta2 glycoprotein I extends our undertsanding of antiphospholipid binding epitopes and may lead to the development of novel therapeutic candidate peptides.
    Ioannou, Yiannis
    Pericleous, Charis
    Latchman, David S.
    Isenberg, David A.
    Raliman, Anisur
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S560 - S560
  • [9] Structural insight into the role of novel SARS-CoV-2 E protein: A potential target for vaccine development and other therapeutic strategies
    Sarkar, Manish
    Saha, Soham
    PLOS ONE, 2020, 15 (08):
  • [10] Development of a bivalent protein-based vaccine candidate against invasive pneumococcal diseases based on novel pneumococcal surface protein A in combination with pneumococcal histidine triad protein D
    Afshari, Elnaz
    Ahangari Cohan, Reza
    Shams Nosrati, Mohammad Sadegh
    Mousavi, Seyed Fazlollah
    FRONTIERS IN IMMUNOLOGY, 2023, 14